Market Cap 10.21M
Revenue (ttm) 1.27M
Net Income (ttm) -69.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,487.40%
Debt to Equity Ratio 0.00
Volume 4,441,100
Avg Vol 2,286,226
Day's Range N/A - N/A
Shares Out 41.03M
Stochastic %K 8%
Beta 0.40
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical tria...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
defineme44
defineme44 Jul. 4 at 6:42 PM
$VTGN then why post?
0 · Reply
Robertigno
Robertigno Jul. 4 at 6:16 PM
$VTGN da quando e' stata quotata non ha mai fatto bene wuesta azione. Mi sembra siano indiani e di farmaci poco ne capiscono.
0 · Reply
bioland
bioland Jul. 4 at 5:30 PM
$VTGN This board is delusional
0 · Reply
actiontime77
actiontime77 Jul. 4 at 4:14 PM
$VTGN i'm so glad I was able to get more shares Thursday
0 · Reply
defineme44
defineme44 Jul. 4 at 3:20 PM
$VTGN i had time read through the filings the 90 days is legit. Thank you to the posters. July 21 deadline its real and a catalyst 🚀 Happy 4th of July 🇺🇸 🎇
0 · Reply
smooth2222
smooth2222 Jul. 4 at 3:22 AM
$VTGN Wouldn’t it be better for Fuji to just buy them out?
0 · Reply
smooth2222
smooth2222 Jul. 4 at 2:52 AM
$VTGN “Because Vistagen received its FDA "Study May Proceed" letter on April 22, 2026, the company is currently right in the middle of this setup window. This positions the trial to physically launch between July and October 2026” From AI
0 · Reply
smooth2222
smooth2222 Jul. 4 at 2:46 AM
$VTGN “Standard Biotech Licensing StructuresWhile the exact numbers are under wraps, a definitive agreement for a Phase II psychiatric/women's health drug like Refisolone typically requires Fuji Pharma to pay Vistagen across three categories:A Larger Upfront Signing Fee: A lump-sum cash payment due immediately upon signing the contract (minus the $1.5 million credit).Development & Regulatory Milestones: Future cash payments triggered when the drug hits specific targets, such as starting Phase III trials in Japan or getting official approval from Japan's PMDA.Commercial Royalties: Percentage-based tier payments paid to Vistagen on all future net sales of the nasal spray within the Japanese market.” From AI
0 · Reply
smooth2222
smooth2222 Jul. 4 at 2:43 AM
$VTGN AI is incredible, “The final deadline for Fuji Pharma to lock down the exclusive licensing agreement with Vistagen is July 21, 2026.” Per AI
0 · Reply
Sorted_Details
Sorted_Details Jul. 3 at 10:00 PM
$VTGN Typically companies will want to announce study may proceed asap. They announced april 22. SEC rules generally consider this a material event requiring 8-k filing within 4 business days. They filed the 8-k 4 business days later on april 28. Despite the 10-k stating june 20th as their estimated expiration for the fuji exclusive negations period, I think its more likely July 20, and the 10-k was a typo. Regardless, the exclusivity is sort of meaningless. It does not force either party to an agreement, and Vistagen would generally be incentivized to let it expire. However, July 20th happens to be the last day that the stock must start closing at over $1 per share to fulfill the 10 day rule needed to be back in compliance with nasdaq. This adds a wrinkle because it creates a counter incentive to make a deal before July 20th, which would necessarily be with Fuji. Given this is just for Japan, I don’t see as many other bidders than larger regions.
1 · Reply
Latest News on VTGN
Vistagen Therapeutics Transcript: Study update

Jun 30, 2026, 8:30 AM EDT - 4 days ago

Vistagen Therapeutics Transcript: Study update


Vistagen Therapeutics Press release: Study update

Jun 30, 2026, 8:30 AM EDT - 4 days ago

Vistagen Therapeutics Press release: Study update


Vistagen Therapeutics Earnings release: Q4 2026

Jun 15, 2026, 4:00 PM EDT - 18 days ago

Vistagen Therapeutics Earnings release: Q4 2026


Vistagen Therapeutics Annual report: Q4 2026

Jun 15, 2026, 4:00 PM EDT - 18 days ago

Vistagen Therapeutics Annual report: Q4 2026


Vistagen appoints Angelov as Chief Medical Officer

2026-05-19T12:37:06.000Z - 6 weeks ago

Vistagen appoints Angelov as Chief Medical Officer


Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 9:00 AM EDT - 3 months ago

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum


Vistagen to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:30 AM EST - 4 months ago

Vistagen to Participate in Upcoming Investor Conferences


Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Feb 12, 2026, 5:00 PM EST - 5 months ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2026


Vistagen Therapeutics Quarterly report: Q3 2026

Feb 12, 2026, 5:00 PM EST - 5 months ago

Vistagen Therapeutics Quarterly report: Q3 2026


Vistagen Therapeutics Earnings release: Q3 2026

Feb 12, 2026, 5:00 PM EST - 5 months ago

Vistagen Therapeutics Earnings release: Q3 2026


Vistagen downgraded to Hold from Buy at Jefferies

2025-12-17T19:25:24.000Z - 7 months ago

Vistagen downgraded to Hold from Buy at Jefferies


Vistagen downgraded to Hold from Buy at Maxim

2025-12-17T17:20:14.000Z - 7 months ago

Vistagen downgraded to Hold from Buy at Maxim


Vistagen downgraded to Hold from Buy at Stifel

2025-12-17T15:45:17.000Z - 7 months ago

Vistagen downgraded to Hold from Buy at Stifel


Vistagen downgraded to Neutral from Buy at Lucid Capital

2025-12-17T14:40:46.000Z - 7 months ago

Vistagen downgraded to Neutral from Buy at Lucid Capital


Vistagen SAD study did not achieve primary endpoint

2025-12-17T14:05:58.000Z - 7 months ago

Vistagen SAD study did not achieve primary endpoint


VistaGen Therapeutics trading resumes

2025-12-17T13:55:10.000Z - 7 months ago

VistaGen Therapeutics trading resumes


VistaGen Therapeutics trading halted, news pending

2025-12-17T13:25:17.000Z - 7 months ago

VistaGen Therapeutics trading halted, news pending


Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 7 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer


Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Nov 13, 2025, 5:00 PM EST - 8 months ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2026


Vistagen Therapeutics Quarterly report: Q2 2026

Nov 13, 2025, 5:00 PM EST - 8 months ago

Vistagen Therapeutics Quarterly report: Q2 2026


Vistagen Therapeutics Earnings release: Q2 2026

Nov 13, 2025, 5:00 PM EST - 8 months ago

Vistagen Therapeutics Earnings release: Q2 2026


Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025


Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 8 months ago

Vistagen Appoints Paul Edick to its Board of Directors


Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting


Vistagen Therapeutics Transcript: AGM 2025

Sep 9, 2025, 12:00 PM EDT - 10 months ago

Vistagen Therapeutics Transcript: AGM 2025


Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2026


Vistagen Therapeutics Quarterly report: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Vistagen Therapeutics Quarterly report: Q1 2026


Vistagen Therapeutics Earnings release: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Vistagen Therapeutics Earnings release: Q1 2026


Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing


Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing


Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2025


Vistagen Therapeutics Earnings release: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q4 2025


Vistagen Therapeutics Annual report: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Annual report: Q4 2025


defineme44
defineme44 Jul. 4 at 6:42 PM
$VTGN then why post?
0 · Reply
Robertigno
Robertigno Jul. 4 at 6:16 PM
$VTGN da quando e' stata quotata non ha mai fatto bene wuesta azione. Mi sembra siano indiani e di farmaci poco ne capiscono.
0 · Reply
bioland
bioland Jul. 4 at 5:30 PM
$VTGN This board is delusional
0 · Reply
actiontime77
actiontime77 Jul. 4 at 4:14 PM
$VTGN i'm so glad I was able to get more shares Thursday
0 · Reply
defineme44
defineme44 Jul. 4 at 3:20 PM
$VTGN i had time read through the filings the 90 days is legit. Thank you to the posters. July 21 deadline its real and a catalyst 🚀 Happy 4th of July 🇺🇸 🎇
0 · Reply
smooth2222
smooth2222 Jul. 4 at 3:22 AM
$VTGN Wouldn’t it be better for Fuji to just buy them out?
0 · Reply
smooth2222
smooth2222 Jul. 4 at 2:52 AM
$VTGN “Because Vistagen received its FDA "Study May Proceed" letter on April 22, 2026, the company is currently right in the middle of this setup window. This positions the trial to physically launch between July and October 2026” From AI
0 · Reply
smooth2222
smooth2222 Jul. 4 at 2:46 AM
$VTGN “Standard Biotech Licensing StructuresWhile the exact numbers are under wraps, a definitive agreement for a Phase II psychiatric/women's health drug like Refisolone typically requires Fuji Pharma to pay Vistagen across three categories:A Larger Upfront Signing Fee: A lump-sum cash payment due immediately upon signing the contract (minus the $1.5 million credit).Development & Regulatory Milestones: Future cash payments triggered when the drug hits specific targets, such as starting Phase III trials in Japan or getting official approval from Japan's PMDA.Commercial Royalties: Percentage-based tier payments paid to Vistagen on all future net sales of the nasal spray within the Japanese market.” From AI
0 · Reply
smooth2222
smooth2222 Jul. 4 at 2:43 AM
$VTGN AI is incredible, “The final deadline for Fuji Pharma to lock down the exclusive licensing agreement with Vistagen is July 21, 2026.” Per AI
0 · Reply
Sorted_Details
Sorted_Details Jul. 3 at 10:00 PM
$VTGN Typically companies will want to announce study may proceed asap. They announced april 22. SEC rules generally consider this a material event requiring 8-k filing within 4 business days. They filed the 8-k 4 business days later on april 28. Despite the 10-k stating june 20th as their estimated expiration for the fuji exclusive negations period, I think its more likely July 20, and the 10-k was a typo. Regardless, the exclusivity is sort of meaningless. It does not force either party to an agreement, and Vistagen would generally be incentivized to let it expire. However, July 20th happens to be the last day that the stock must start closing at over $1 per share to fulfill the 10 day rule needed to be back in compliance with nasdaq. This adds a wrinkle because it creates a counter incentive to make a deal before July 20th, which would necessarily be with Fuji. Given this is just for Japan, I don’t see as many other bidders than larger regions.
1 · Reply
joe77w
joe77w Jul. 3 at 6:10 PM
$VTGN https://www.otcmarkets.com/filing/html?id=19539065&guid=IHF-knwhj2fOOth Agreement with FUJI, I don't know if still ongoing or terminated, in the 10K issued on June 15 2026.
2 · Reply
joe77w
joe77w Jul. 3 at 6:09 PM
$VTGN As consideration for the Exclusive Negotiation Period, we received from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji Pharma enter into the Potential Definitive Agreement, the Purchase Price will be credited against any upfront fee due in connection with the execution of such agreement. Neither we nor Fuji Pharma are obligated to enter into the Potential Definitive Agreement, and if we and Fuji Pharma have not entered into the Potential Definitive Agreement on or before the end of the Exclusive Negotiation Period, either party may terminate any further negotiations.
0 · Reply
joe77w
joe77w Jul. 3 at 6:08 PM
$VTGN The Negotiation Agreement provides for an exclusive negotiation period beginning on the date of formal written notice being received by Fuji Pharma that we have selected a CDMO to conduct certain toxicology studies for the product candidate (Payment Event), and terminating on the later to occur of (i) fourteen (14) months from the date of the Payment Event or (ii) ninety (90) days from the date that the FDA accepts an IND application for refisolone for the treatment of vasomotor symptoms (hot flashes) due to menopause (Exclusive Negotiation Period). Following the receipt of the Study May Proceed letter from the FDA under our U.S. IND for refisolone, we expect the Exclusive Negotiation Period will end on or about June 20, 2026.
0 · Reply
joe77w
joe77w Jul. 3 at 6:07 PM
$VTGN Exclusive Negotiation Agreement with Fuji Pharma Co., LTD. On September 1, 2023, we entered into an Exclusive Negotiation Agreement (the Negotiation Agreement) with Fuji Pharma Co., Ltd. (Fuji Pharma), a Tokyo Stock Exchange-listed, Japan-based pharmaceutical company. Pursuant to the terms and conditions of the Negotiation Agreement, we agreed, for a limited period of time, to negotiate exclusively with Fuji Pharma a potential exclusive license agreement, to develop and commercialize refisolone in Japan (the Potential Definitive Agreement).
0 · Reply
Robertigno
Robertigno Jul. 3 at 2:59 PM
$VTGN seguo questa azienda dal 2018.... non mi aspettavo un'altra mancata approvazione. Adesso????
0 · Reply
Edgebell
Edgebell Jul. 3 at 1:47 PM
$VTGN. Call me crazy and most will say so There may be a true silver lining about to happen. Refisolone was accepted bybfda to proceed forward on April 22. Fuji now has 90 days (July 21) to make a deal for Japan rights. That deal is estimated $10-20m upfront. Perhaps $50M in milestones. Here is fujis plan. Good solid plan https://www.fujipharma.jp/english/ir/management_plan/
1 · Reply
Mnpois
Mnpois Jul. 3 at 2:40 AM
$VTGN tippp
0 · Reply
Sorted_Details
Sorted_Details Jul. 3 at 2:16 AM
$VTGN while they wait to advance fasedienol, they should immediately pivot to initiating phase 2b for PH80. The trial can be done relatively cheaply and quickly. The trial design is less troublesome, and a positive readout would put them in a much stronger position to raise capital later. Cash on hand should support this.
0 · Reply
actiontime77
actiontime77 Jul. 3 at 1:05 AM
$VTGN just been adding here. It will go
0 · Reply
R0MER0
R0MER0 Jul. 2 at 8:36 PM
$VTGN 👀
2 · Reply
marketCaptain
marketCaptain Jul. 2 at 8:32 PM
$VTGN Singh and nick Tressler bought The dip yeterday
0 · Reply
joe77w
joe77w Jul. 2 at 8:30 PM
$VTGN https://www.otcmarkets.com/filing/html?id=19587364&guid=3WF-keWSJ-bdB3h
0 · Reply